Advertisement

Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis

      Abstract

      Purpose

      Andecaliximab (GS-5745) is a highly selective monoclonal antibody against matrix metalloproteinase-9 (MMP9), a proteolytic enzyme implicated in the pathogenesis of rheumatoid arthritis (RA). This study assessed the safety and pharmacokinetic (PK) parameters of andecaliximab in patients with RA and evaluated the effects of andecaliximab treatment on exploratory disease biomarkers.

      Methods

      In this double-blind, Phase 1b trial, patients with active RA were randomized (4:1) to receive 400-mg andecaliximab or placebo every 2 weeks for a total of 3 intravenous infusions. The primary and secondary end points were safety and the PK parameters of andecaliximab, respectively. Data were summarized by using descriptive statistics.

      Findings

      A total of 18 patients were randomized; 15 received andecaliximab (participants with confirmed RA diagnosis without current administration of a biologic DMARD a biologic DMARD (disease-modifying antirheumatic drug), aged 18 to 70 years old, weighing >45 to <120 kg). No deaths, serious adverse events, or study discontinuations occurred. All reported adverse events were grade 1 or grade 2 in severity. Mean plasma andecaliximab exposure was 587 d · µg/mL and 878 d · µg/mL at days 1 and 29, respectively, suggesting moderate accumulation. The median terminal t1/2 was 5.65 days; mean volume of distribution at steady state was 4560 mL. Mean MMP9 coverage (the percentage of total plasma MMP9 bound by therapeutic antibody) was maintained at ~80% after the first administration of andecaliximab.

      Implications

      Andecaliximab administered as 3 infusions over 29 days was generally safe and well tolerated in patients with RA. The majority of total plasma MMP9 was bound by andecaliximab after the first administration. Clinical studies of increased treatment duration in larger patient cohorts are warranted. ClinicalTrials.gov identifier: NCT02176876. Registered on 25 June 2014.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Aletaha D.
        • Neogi T.
        • Silman A.J.
        • et al.
        2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
        Ann Rheum Dis. 2010; 69: 1580-1588
        • Cross M.
        • Smith E.
        • Hoy D.
        • et al.
        The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study.
        Ann Rheum Dis. 2014; 73: 1316-1322
        • Sokka T.
        • Kautiainen H.
        • Pincus T.
        • et al.
        Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study.
        Arthritis Res Ther. 2010; 12: R42
        • Salaffi F.
        • Carotti M.
        • Gasparini S.
        • et al.
        The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people.
        Health Qual Life Outcomes. 2009; 7: 25
        • Young A.
        • Koduri G.
        • Batley M.
        • et al.
        Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis.
        Rheumatology (Oxford). 2007; 46: 350-357
        • Smolen J.S.
        • Aletaha D.
        • McInnes I.B.
        Rheumatoid arthritis.
        Lancet. 2016; 388: 2023-2038
        • Smolen J.S.
        • Landewe R.
        • Breedveld F.C.
        • et al.
        EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.
        Ann Rheum Dis. 2014; 73: 492-509
        • Gibofsky A.
        Current therapeutic agents and treatment paradigms for the management of rheumatoid arthritis.
        Am J Manag Care. 2014; 20: S136-S144
        • Deighton C.
        • O'Mahony R.
        • Tosh J.
        • et al.
        • Guideline Development Group
        Management of rheumatoid arthritis: summary of NICE guidance.
        BMJ. 2009; 338: b702
        • Singh J.A.
        • Saag K.G.
        • Bridges Jr., S.L.
        • et al.
        2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
        Arthritis Rheumatol. 2016; 68: 1-26
        • Tchetverikov I.
        • Lard L.R.
        • DeGroot J.
        • et al.
        Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis.
        Ann Rheum Dis. 2003; 62: 1094-1099
        • Kaneko M.
        • Tomita T.
        • Nakase T.
        • et al.
        Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis.
        Rheumatology (Oxford). 2001; 40: 247-255
        • Ahrens D.
        • Koch A.E.
        • Pope R.M.
        • et al.
        Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis.
        Arthritis Rheum. 1996; 39: 1576-1587
        • Yoshihara Y.
        • Nakamura H.
        • Obata K.
        • et al.
        Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.
        Ann Rheum Dis. 2000; 59: 455-461
        • Hu J.
        • Van den Steen P.E.
        • Sang Q.X.
        • Opdenakker G.
        Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.
        Nat Rev Drug Discov. 2007; 6: 480-498
        • Gearing A.J.
        • Beckett P.
        • Christodoulou M.
        • et al.
        Matrix metalloproteinases and processing of pro-TNF-alpha.
        J Leukoc Biol. 1995; 57: 774-777
        • Xue M.
        • McKelvey K.
        • Shen K.
        • et al.
        Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation.
        Rheumatology (Oxford). 2014; 53: 2270-2279
        • Ramos-DeSimone N.
        • Hahn-Dantona E.
        • Sipley J.
        • et al.
        Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion.
        J Biol Chem. 1999; 274: 13066-13076
        • Keystone E.
        Treatments no longer in development for rheumatoid arthritis.
        Ann Rheum Dis. 2002; 61: ii43-ii45
        • Krzeski P.
        • Buckland-Wright C.
        • Balint G.
        • et al.
        Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study.
        Arthritis Res Ther. 2007; 9: R109
        • Marshall D.C.
        • Lyman S.K.
        • McCauley S.
        • et al.
        Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer.
        PLoS One. 2015; 10: e0127063
        • Appleby T.C.
        • Greenstein A.E.
        • Hung M.
        • et al.
        Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9.
        J Biol Chem. 2017; 292: 6810-6820
        • Arnett F.C.
        • Edworthy S.M.
        • Bloch D.A.
        • et al.
        The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
        Arthritis Rheum. 1988; 31: 315-324
        • U.S. Department of Health and Human Services
        Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
        NIH Publication No. 09-5410. 2010;
        • Wells G.
        • Becker J.C.
        • Teng J.
        • et al.
        Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.
        Ann Rheum Dis. 2009; 68: 954-960
        • Segurado O.G.
        • Sasso E.H.
        Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis.
        Clin Exp Rheumatol. 2014; 32: S-29-S-34
        • Ward M.M.
        • Guthrie L.C.
        • Alba M.I.
        Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials.
        Ann Rheum Dis. 2015; 74: 1691-1696
        • Anderson J.
        • Caplan L.
        • Yazdany J.
        • et al.
        Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.
        Arthritis Care Res (Hoboken). 2012; 64: 640-647
        • Bendell J.C.
        • Starodub A.
        • Shah M.A.
        • et al.
        Phase 1 study of GS-5745 alone and in combination with chemotherapy in patients with advanced solid tumors.
        2015 ASCO Annual Meeting. 2015; : 4030
        • Sandborn W.J.
        • Bhandari B.R.
        • Fogel R.
        • et al.
        Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.
        Aliment Pharmacol Ther. 2016; 44: 157-169